In vitro activity of pyrvinium pamoate against Entamoeba histolytica and Giardia intestinalis using radiolabelled thymidine incorporation and an SYBR Green I-based fluorescence assay

Autumn S. Downey, Thaddeus K. Graczyk, David J. Sullivan

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives: To assess the in vitro activity of the FDA-approved antihelminthic drug pyrvinium pamoate against Entamoeba histolytica and Giardia intestinalis. Methods: A head-to-head comparison of a standard radiolabelled thymidine incorporation assay and the SYBR Green I-based fluorescence assay for determination of in vitro inhibition by pyrvinium and metronidazole was performed. Results: The 50% inhibitory concentration (IC50) for treatment of E. histolytica with pyrvinium was 4-5 μM for both assays compared with 1-2 μM for metronidazole. For pyrvinium treatment of G. intestinalis, an IC50 of ∼12 μM was determined by the radiolabelled thymidine assay alone, with maximum inhibition around 60%. In contrast, the IC50 for metronidazole treatment using this assay was ∼2 μM. Conclusions: Pyrvinium is a potential gut lumen agent for treatment of intestinal amoebiasis, but possibly not for giardiasis. SYBR Green I is an alternative screening method for E. histolytica, but not G. intestinalis.

Original languageEnglish (US)
Pages (from-to)751-754
Number of pages4
JournalJournal of Antimicrobial Chemotherapy
Volume64
Issue number4
DOIs
StatePublished - 2009

Keywords

  • Drug
  • Drug assay
  • Protozoan

ASJC Scopus subject areas

  • Pharmacology
  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'In vitro activity of pyrvinium pamoate against Entamoeba histolytica and Giardia intestinalis using radiolabelled thymidine incorporation and an SYBR Green I-based fluorescence assay'. Together they form a unique fingerprint.

Cite this